Immuron Limited
Index- P/E- EPS (ttm)-1.08 Insider Own- Shs Outstand5.68M Perf Week0.73%
Market Cap15.62M Forward P/E- EPS next Y- Insider Trans- Shs Float4.56M Perf Month-10.71%
Income- PEG- EPS next Q- Inst Own2.69% Short Float0.05% Perf Quarter-4.84%
Sales0.36M P/S43.83 EPS this Y- Inst Trans- Short Ratio0.22 Perf Half Y-16.67%
Book/sh4.56 P/B0.60 EPS next Y- ROA- Target Price- Perf Year-59.38%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.32 - 5.20 Perf YTD10.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.12% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low18.53% ATR0.19
Employees- Current Ratio- Sales Q/Q1037.30% Oper. Margin- RSI (14)44.79 Volatility4.98% 6.88%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.16 Prev Close2.74
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume9.93K Price2.75
Recom2.00 SMA20-3.57% SMA50-8.99% SMA200-22.79% Volume1,549 Change0.36%
May-11-22 06:00AM  
May-09-22 06:00AM  
May-05-22 08:22PM  
Apr-27-22 06:00AM  
Apr-19-22 07:33AM  
Mar-25-22 05:21AM  
Mar-16-22 09:30AM  
Jan-17-22 06:00AM  
Jan-13-22 06:00AM  
Jan-12-22 02:58PM  
Nov-15-21 06:00AM  
Nov-10-21 06:00AM  
Oct-08-21 08:10AM  
Sep-24-21 08:40PM  
Sep-23-21 11:00PM  
May-13-21 06:00AM  
Mar-02-21 11:40AM  
Jan-11-21 06:00AM  
Dec-15-20 06:00AM  
Nov-24-20 06:00AM  
Nov-11-20 06:00AM  
Oct-12-20 06:00AM  
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.